Myasthenia gravis (MG) is one of the autoantibody-mediated neuroimmunological diseases. Autoantibodies to the muscle-type nicotinic acetylcholine receptor (AChR) were detected in more than 80% of MG patients. The gene structure and pathogenicity of some AChR antibodies produced in MG have already been identified and elucidated, respectively. Therefore, the AChR antibody is similar in nature to innovative drug development targets with respect to MG treatment. Here, we discuss the development of molecular target drugs for AChR antibody-positive MG.